OrbiMed — 2018 Investments
4 investments dated 2018 · listed companies and verified rows first · show all
Emergent BioSolutions is a public health company that develops, manufactures, and supplies medical countermeasures for national security and preparedness, along with commercialized products addressing threats such as the opioid epidemic.
Advanced ManufacturingBiotechHealthtechGaithersburg, US
Fuad El-Hibri(Director, Executive Officer)Robert G Kramer(Executive Officer)Katherine Strei(Executive Officer)Adam R Havey(Executive Officer)Daniel J Abdun-Nabi(Executive Officer, Director)Zsolt Harsanyi(Director)
Co-investorsAdvent Life Sciences
BiotechLaval
Francois Desjardins(Vice President, Finance)Denis Garceau(Senior Vice President, Drug Development)Franklin Berger(Director)Roberto Bellini(President and Chief Executive Officer)Joseph Rus(Director)Youssef L. Bennani(Director)
Board seatChau Khuong· per SEC Form D · $24M raise · filed Jan 2019
HealthtechNew York, US
ASA ABELIOVICH(Executive Officer, Director)
Board seatCarl GordonPeter ThompsonMona Ashiya· per SEC Form D · $65M raise · filed Mar 2018
BiotechCambridge, US
William C. Shakespeare(Director)
BoardIain Dukes(Executive Officer, Director)inMichael Rome(Director)
Board seatCarl Gordon· per SEC Form D
Co-investorsForesite CapitalLongitude CapitalNextech Invest
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.